close read more

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Press contact : – presse@servier.com

Press release

Press release
Servier certified Top Employer Europe 2022
Press release
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
Press release
Aqemia and Servier announce AI and quantum physics-driven drug discovery collaboration in immuno-oncology
Press release
Servier joins the Act4Nature International initiative
Press release
Pieris Pharmaceuticals and Servier announce dosing of first patient in phase 1/2 trial of 4-1BB/PD-L1 bispecific PRS-344/S095012
Press release
Servier and Guangdong Maijinjia Biotechnologies Co. LTD, and Ranger Biotechnologies enter into a Research Collaboration to develop a novel therapy for treating proteinopathies in rare neurodegenerative diseases
Press release
Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents
Press release
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Press release
Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics